ROCKET PHARMACEUTICALS (NASDAQ: RCKT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by August 11, 2025

Core Viewpoint - Berger Montague PC is investigating Rocket Pharmaceuticals for potential violations of federal securities laws related to the RP-A501 trial, which allegedly concealed safety concerns leading to significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, focusing on research and clinical programs in genetic medicine [2]. - The company introduced a new immunomodulatory agent into the RP-A501 protocol without disclosing this information to shareholders, which preceded a fatal adverse event [2]. Stock Performance - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Legal Proceedings - A class action has been filed for individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, with a deadline to file for lead plaintiff set for August 11, 2025 [3].